Fox Run Management L.L.C. Sells 41,121 Shares of Amicus Therapeutics, Inc. $FOLD

Key Points

• Fox Run Management L.L.C. significantly reduced its holdings in Amicus Therapeutics (NASDAQ:FOLD) by 65.7%, selling 41,121 shares and leaving it with 21,449 shares valued at approximately $175,000.
• Despite the reduction from Fox Run, other hedge funds like PNC Financial Services and GAMMA Investing have increased their stakes, indicating mixed activity among institutional investors in Amicus Therapeutics.
• Recent analyst reports have shown a generally positive outlook, with upgrades from firms like Morgan Stanley and UBS, and a target price averaging around $16.22 for the stock.

Fox Run Management L.L.C. reduced its position in Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 65.7% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 21,449 shares of the biopharmaceutical company's stock after selling 41,121 shares during the period. Fox Run Management L.L.C.'s holdings in Amicus Therapeutics were worth $175,000 at the end of the most recent quarter.

A number of other hedge funds also recently made changes to their positions in FOLD. Envestnet Asset Management Inc. lifted its position in shares of Amicus Therapeutics by 1.7% in the fourth quarter. Envestnet Asset Management Inc. now owns 425,419 shares of the biopharmaceutical company's stock worth $4,007,000 after buying an additional 7,204 shares in the last quarter. Russell Investments Group Ltd. raised its position in shares of Amicus Therapeutics by 539.1% during the 4th quarter. Russell Investments Group Ltd. now owns 53,282 shares of the biopharmaceutical company's stock valued at $502,000 after buying an additional 44,945 shares in the last quarter. Raymond James Financial Inc. purchased a new stake in shares of Amicus Therapeutics during the 4th quarter valued at about $132,000. Marshall Wace LLP raised its position in shares of Amicus Therapeutics by 254.2% during the 4th quarter. Marshall Wace LLP now owns 72,968 shares of the biopharmaceutical company's stock valued at $687,000 after buying an additional 52,368 shares in the last quarter. Finally, CANADA LIFE ASSURANCE Co raised its position in shares of Amicus Therapeutics by 7.4% during the 4th quarter. CANADA LIFE ASSURANCE Co now owns 80,076 shares of the biopharmaceutical company's stock valued at $753,000 after buying an additional 5,522 shares in the last quarter.

Analysts Set New Price Targets

Several analysts have recently issued reports on the stock. The Goldman Sachs Group decreased their target price on shares of Amicus Therapeutics from $12.00 to $9.00 and set a "neutral" rating on the stock in a research report on Friday, May 2nd. UBS Group upped their target price on shares of Amicus Therapeutics from $21.00 to $22.00 and gave the company a "buy" rating in a research report on Friday, May 2nd. Wall Street Zen upgraded shares of Amicus Therapeutics from a "hold" rating to a "buy" rating in a research report on Saturday, August 2nd. Finally, Morgan Stanley raised shares of Amicus Therapeutics from an "equal weight" rating to an "overweight" rating in a research report on Thursday, July 17th. Eight equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $16.22.

Amicus Therapeutics Trading Down 1.5%

Shares of NASDAQ:FOLD traded down $0.1150 during trading on Monday, reaching $7.4950. 1,386,782 shares of the company were exchanged, compared to its average volume of 3,865,249. The firm has a market capitalization of $2.31 billion, a PE ratio of -62.29 and a beta of 0.53. The business's fifty day simple moving average is $6.35 and its 200-day simple moving average is $7.16. Amicus Therapeutics, Inc. has a 12-month low of $5.51 and a 12-month high of $12.65. The company has a debt-to-equity ratio of 1.92, a current ratio of 3.21 and a quick ratio of 2.29.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.